A provider-focused briefing on Cambia availability in 2026, including prescribing considerations, cost barriers, alternative therapies, and tools to help patients.
If your patients have been reporting difficulty filling their Cambia prescriptions, they're not wrong. While Cambia (Diclofenac Potassium for oral solution, 50 mg) is not in a formal FDA-listed shortage, real-world access remains challenging for many patients in 2026. This briefing covers what's driving the availability issues, the prescribing implications, and practical tools to help your patients get the treatment they need.
Cambia is an NSAID formulated as a powder for oral solution, FDA-approved for the acute treatment of migraine attacks with or without aura in adults. Its liquid formulation allows for faster absorption compared to standard Diclofenac tablets, providing rapid onset of migraine relief — typically within 15-30 minutes. It is manufactured by Assertio Therapeutics.
The standard dose is one 50 mg packet dissolved in 1-2 ounces of water, taken as a single dose at migraine onset. It is not indicated for migraine prevention or for use in patients under 18.
Cambia was approved by the FDA in 2009 and has been marketed in the United States since then. Over the years, several factors have converged to create the current availability situation:
When prescribing Cambia, providers should be aware of several practical considerations:
Most commercial insurance plans classify Cambia as a non-preferred brand or Tier 3 medication. Common coverage requirements include:
If prior authorization is denied, appealing with clinical documentation of triptan contraindications (e.g., cardiovascular risk factors) or documented treatment failures can be effective.
As with all NSAIDs, Cambia carries a boxed warning for:
These warnings are particularly relevant when evaluating Cambia against triptan alternatives, which carry their own cardiovascular contraindications. For patients with significant CV risk, CGRP receptor antagonists (gepants) may be the preferred alternative. For a comprehensive review of interactions, see Cambia Drug Interactions: What to Avoid.
Cambia is not on the FDA drug shortage list as of February 2026. The manufacturer reports normal production. However, real-world availability is limited by:
Understanding the cost picture helps providers set appropriate expectations with patients:
Providers should routinely recommend that uninsured or underinsured patients check discount card pricing, which can reduce cost by over 90%.
Several tools can help streamline the process of getting patients their Cambia prescriptions:
Medfinder for Providers allows you to check real-time pharmacy availability for Cambia near your patient's location. This eliminates the guesswork of sending prescriptions to pharmacies that may not stock the medication.
When Cambia is unavailable or inappropriate, evidence-based alternatives include:
For a detailed comparison, refer patients to Alternatives to Cambia If You Can't Fill Your Prescription.
The availability outlook for Cambia in 2026 and beyond depends on several factors:
Cambia remains a clinically valuable option for acute migraine treatment, particularly for patients who prefer an NSAID approach or have contraindications to triptans. The primary barriers in 2026 are practical — cost, insurance coverage, and pharmacy stocking — rather than supply-related.
By using tools like Medfinder for Providers, discussing cost-saving strategies proactively, and maintaining awareness of alternative options, providers can help their migraine patients navigate these access challenges effectively.
Additional provider resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
